NICE no longer recommends omalizumab for asthma . . .

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.667, 2012-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NICE recommends four drugs

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 644, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

NICE recommends nilotinib and golimumab . . .

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 636, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

NICE recommends rituximab for follicular lymphoma . . .

Inpharma, Vol. 1, Iss. 1559, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

NICE recommends dexamethasone intravitreal implant, . . .

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 631, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years: A NICE Single Technology Appraisal

By Burch Jane

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 991-1004

Adis International

Access to resources Recommend Favorite